Execution architecture for regulated procurement.

S2P transformation under regulated pressure.

Situation: the program is live but drifting; Monday looks the same. Risk: supplier friction and cost leakage compound while audit exposure grows. Intervention: execution diagnosis of ownership, decision rights and handoffs across the procurement–finance–quality interfaces. Boundary: a system diagnosis — not a validation or compliance service.

ERP / S/4HANA decision rights.

Situation: master data, outline agreements and release strategies have no clear owner. Risk: the go-live hardens broken governance into the system. Intervention: a System Review of ownership and controls before the architecture question hardens — see the S/4HANA outline agreement control case. Boundary: decision support — not implementation or certification.

Supply continuity and critical suppliers.

Situation: multi-site supply with concentrated external dependencies. Risk: a single break cascades across markets. Intervention: resilience read of the operating model and cross-functional handoffs — see the global shipment resilience use case. Boundary: execution architecture — not demand planning or QP release.

Shared services, GBS and P2P controls.

Situation: the shared-service layer compensates for weak upstream ownership. Risk: cost and control erode quietly, invoice by invoice. Intervention: P2P operating-model review with documented value logic — USD 1M+ reported P2P cost reduction and USD 450K reported cost avoidance in the proof library, with explicit evidence classes and boundaries. Boundary: reported figures, not certified savings.

Animal health, lived end to end.

Three years inside Elanco as Global Process Owner & Director P2P and Procurement PMO:

• Stabilization lead for the carved-out Bayer Animal Health business — shared services, accounts payables, P2P, vendor master data, controls and governance.
• Transformation change agent for 4,000+ employees across 40+ countries.
• P2P organization moved from 30 to 17 experts — carried by a global power-user concept: 130 power users and 35 captains across 35 countries, rolled out in three months.
• Owner of 12 P2P SoX controls; data domain owner for SAP purchase contracts.
• Top Performance Awards 2020 and 2021; Q3/22 Voice-of-the-Employee score roughly 25% above company average in participation and engagement.

Pharma sourcing with a named outcome.

Bayer AG, Leverkusen (2019):

• Project procurement lead for strategic sourcing and project management of laboratory scale devices in the pharma division.
• EUR 1,000,000 in savings — a named-environment career outcome.
• Classified Class A in the KULIC evidence registry.

Pharma procurement, client-evaluated.

GSK Vaccines Belgium (2015):

• Senior consultant for indirect procurement across CAPEX, OPEX, facility, maintenance, services and spare parts — with direct links to the Novartis integration.
• Interim mandate as Global Sourcing Category Manager for secondary process equipment.
• Mission evaluated by the client’s Director Indirect Procurement; award for best procurement consultancy performance on assignment.
• Award for best project management in real-estate and facility projects; advisory role to the purchasing director on Novartis-acquisition synergies.
• The full portfolio closed EUR 1.5M under budget — the Class A reference case.

Group-wide S2P architecture, by mandate.

Merck Group, Darmstadt (2025–2026), Senior Advisor Procurement:

• Architect of the end-to-end Source-to-Pay process across the whole Merck group.
• Governance architecture for the E2E process.
• Blueprint for the GPO S2P role archetype for Group Procurement.
• The most recent named environment in this record — S2P execution architecture at group scale.

Evidence classes on every claim.

Every figure in the proof library carries its evidence class:

• Class A — validated reference outcomes: GSK Vaccines Belgium 2015, closed EUR 1.5M under budget; Bayer Pharma 2019, EUR 1,000,000 in savings.
• Class B — implemented outcomes: S/4HANA outline agreement control; USD 450K reported cost avoidance; USD 1M+ reported P2P cost reduction.
• Class C — modeled value potential: approx. 4M modeled AICTIONBOT™ value potential.
• Class D — effort signal supporting the Class C model.

The honest boundary.

These are employment and assignment contexts from a documented, publicly verifiable career in life sciences. Published proof cases remain industry-neutral by design, and none of this implies current client relationships. Boundaries are stated before outcomes.